IGF-1 DES vs Sermorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
IGF-1 DES
IGF-1 DES (Des(1-3)IGF-1) is the naturally occurring truncated form of IGF-1, lacking the first three N-terminal amino acids (Gly-Pro-Glu). This small structural difference produces a dramatically more potent molecule: by removing the primary IGF binding protein (IGFBP-3) attachment site, IGF-1 DES circulates in free form with approximately 10x higher potency than standard IGF-1 LR3 at equivalent doses. It acts locally in tissue rather than systemically, making it the preferred form for targeted muscle hypertrophy research.
Full profileSermorelin
Sermorelin is a synthetic analog of the first 29 amino acids of GHRH (Growth Hormone-Releasing Hormone). It was FDA-approved for pediatric GH deficiency diagnosis and is widely used off-label in anti-aging and performance medicine. It stimulates pulsatile GH release more physiologically than exogenous GH.
Full profile| IGF-1 DES | Sermorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Des(1-3)IGF-1, Truncated IGF-1, DES-IGF-1 | GHRH 1-29, GRF 1-29 NH2, Geref |
| Evidence | Research-stage | FDA-approved |
| Dosing range | 50mcg–150mcg mcg, 1–2x daily, preferably post-workout | 100mcg–500mcg mcg, once daily (before sleep) |
| Administration | Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect) | Subcutaneous injection |
| Key side effects | Hypoglycemia (potent insulin-like effect — have fast carbohydrates nearby), Localized muscle swelling at injection site, Jaw pain / facial bone growth at very high doses (acromegaly-like — dose-dependent), Organ enlargement at excessive doses | Injection site redness, Headache, Flushing, Dizziness |
| Cited sources | 2 references | 1 reference |
Key differences
- Evidence level differs: IGF-1 DES is research-stage, while Sermorelin is fda-approved.
- Administration: IGF-1 DES — Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect); Sermorelin — Subcutaneous injection.
- Frequency: IGF-1 DES is typically 1–2x daily, preferably post-workout; Sermorelin is once daily (before sleep).
- Research depth: this profile cites 2 sources for IGF-1 DES vs 1 for Sermorelin.
How each works
IGF-1 DES
The three N-terminal amino acids of IGF-1 are the primary binding site for IGFBP-3 (IGF binding protein 3), which sequesters 75–90% of circulating IGF-1 in an inactive bound form. IGF-1 DES lacks this binding site, meaning virtually all injected peptide reaches tissue receptors as free (active) IGF-1. In skeletal muscle research, Des-IGF-1 promotes satellite cell activation, myoblast proliferation, and differentiation at lower doses than LR3. It has a shorter half-life (~20–30 minutes) than LR3 but acts more intensely — particularly at the site of injection.
Sermorelin
Sermorelin works by binding pituitary GHRH receptors to stimulate GH secretion within the body's natural feedback loop. Unlike synthetic GH, it does not suppress endogenous production. Clinical studies show improved body composition, sleep quality, and IGF-1 levels in GH-deficient adults. Its short half-life (~10 min) means it requires daily dosing.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.